International Journal of Molecular Sciences · 2020 · 44 citations · 38 references
Life SciencesBiochemistryCancer BiologyCell SignalingPlant BiochemistrySignal TransductionCell Signaling DisruptionMelanocytic TumorsAnticancer ActivityHeart RateMelanin BiosynthesisMelanin FormationMelanin ProductionMelanin SynthesisMelanization Pathway RegulationMolecular Docking Analysis
Fisetin is found in many fruits and plants such as grapes and onions, and exerts anti-inflammatory, anti-proliferative, and anticancer activity. However, whether fisetin regulates melanogenesis has been rarely studied. Therefore, we evaluated the effects of fisetin on melanogenesis in B16F10 melanoma cell and zebrafish larvae. The current study revealed that fisetin slightly suppressed in vitro mushroom tyrosinase activity; however, molecular docking data showed that fisetin did not directly bind to mushroom tyrosinase. Unexpectedly, fisetin significantly increased intracellular and extracellular melanin production in B16F10 melanoma cells regardless of the presence or absence of α-melanocyte stimulating hormone (α-MSH). We also found that the expression of melanogenesis-related genes such as tyrosinase and microphthalmia-associated transcription factor (MITF), were highly increased 48 h after fisetin treatment. Pigmentation of zebrafish larvae by fisetin treatment also increased at the concentrations up to 200 µM and then slightly decreased at 400 µM, with no alteration in the heart rates. Molecular docking data also revealed that fisetin binds to glycogen synthase kinase-3β (GSK-3β). Therefore, we evaluated whether fisetin negatively regulated GSK-3β, which subsequently activates β-catenin, resulting in melanogenesis. As expected, fisetin increased the expression of β-catenin, which was subsequently translocated into the nucleus. In the functional assay, FH535, a Wnt/β-catenin inhibitor, significantly inhibited fisetin-mediated melanogenesis in zebrafish larvae. Our data suggested that fisetin inhibits GSK-3β, which activates β-catenin, resulting in melanogenesis through the revitalization of MITF and tyrosinase.
38
Jeremy R. Graff, Ann M. McNulty, Kimberly R. Hanna et al. · Cancer Research · 2005 · 437 citations · Full text
Medicine, Oncology, Pharmacology +15
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Eduardo Tolosa, Irene Litvan, Günter U. Höglinger et al. · Movement Disorders · 2014 · 318 citations
Medicine, Neurology, Pharmacology +13